GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.